Key Highlights
- NVNO slid modestly at last closing on heavy trading interest, with only about 0.68 million shares outstanding after a reverse split.
- The FDA cleared enVVeno's IDE for the TAVVE pivotal trial, its first U.S. study of a non-surgical replacement venous valve.
- Cash stood at about $21.5 million at the end of the second quarter of 2026, down from roughly $28.2 million at the close of 2025.
- A new U.S. Patent covering core enVVe components was issued in July 2026.
enVVeno Medical Corporation (NASDAQ:NVNO) has quietly built one of the more distinctive stories among Nasdaq's small-cap medical-device names. The Irvine, California company is developing replacement valves for diseased veins, a corner of vascular medicine with few approved options, and in 2026 it cleared a pivotal regulatory hurdle that could shape its future. The stock, trading under the ticker NVNO, changes hands at a low double-digit price after a reverse split left it with a very small share count, which makes even routine sessions look dramatic. A recent modest daily decline drew attention, though no single confirmed catalyst explains it.
Company and Latest Development
enVVeno Medical, formerly Hancock Jaffe Laboratories, develops bioprosthetic devices to treat chronic venous insufficiency, a progressive condition in which damaged vein valves allow blood to pool in the legs. Its lead program is enVVe, a transcatheter, non-surgical replacement venous valve. On April 29, 2026, the company announced that the U.S. Food and Drug Administration approved its investigational device exemption (IDE) for the TAVVE trial, which enVVeno describes as the first U.S. pivotal study of a non-surgical replacement venous valve. In its July 31, 2026 second-quarter update, the company said the FDA had cleared it to begin enrolling that pivotal trial, targeting roughly 230 patients across up to 40 U.S. sites, with enrollment expected to start in the second half of 2026.
What Is Driving Attention Around NVNO?
The small single-session slide and heavy trading interest do not trace to a specific, verifiable same-day catalyst. With only a few hundred thousand shares outstanding following a reverse split, NVNO's price can move sharply on limited volume, and daily percentage swings frequently reflect thin Liquidity rather than fresh company news. The broader narrative is the pivotal-trial clearance and a steady drumbeat of supporting milestones, including a newly issued U.S. patent (No. 12,575,932) covering core enVVe components in July 2026 and a company-highlighted independent health-economic study in August 2026 projecting meaningful per-patient cost savings.
Key Numbers and Company Position
enVVeno reported cash of about $21.5 million as of the end of the second quarter of 2026, down from roughly $24.9 million at the end of the first quarter and $28.2 million at the close of 2025. For full-year 2025 the company posted a net loss of about $19.5 million, which it said narrowed year over year. Market-data providers list NVNO on Nasdaq with a market Capitalization near $8 million and only about 0.68 million shares outstanding, an unusually small float that reflects the reverse split. The modest capitalization relative to reported cash underscores how thinly the shares trade.
What Could Come Next?
The most consequential near-term catalyst is the start and progress of the TAVVE pivotal trial. Enrollment pace, early safety signals and site activations will be closely followed, as will any additional FDA interactions. Investors may also watch quarterly cash updates, given a clinical-stage burn rate, plus potential financing steps, further patent issuances and any Partnership or commercialization discussions as the pivotal study advances.
Risks to Watch
The risks are considerable. As a pre-revenue, clinical-stage device maker, enVVeno depends on trial success and eventual FDA approval, neither of which is assured. Cash is finite against ongoing losses, raising the prospect of dilutive financing. The tiny share float amplifies Volatility in both directions, and any clinical setback, enrollment delay or safety issue could weigh heavily on sentiment.
A Small Float Ahead of a Pivotal Enrollment
enVVeno Medical enters the second half of 2026 with a rare FDA go-ahead for a pivotal venous-valve trial and a defined clinical path, offset by the funding and execution risks typical of small-cap medtech. With enrollment set to begin, trial milestones and cash runway are likely to be the key developments to monitor.






Please wait processing your request...